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ABSTRACT

A group I intron-derived ribozyme Which binds RNA in trans,
excises an internal segment from Within the RNA, and splices
the remaining 5' and 3' ends of the RNA back together (the

trans-excision-splicing reaction) is disclosed. The excised
segment can be as long as 28 nucleotides, or more, and as little

as one nucleotide. The ribozymes of the invention are easily

modi?ed to alter their sequence speci?city. Such ribozymes
represent a neW and potentially powerful class of generally

adaptable genetic therapeutics.
10 Claims, 8 Drawing Sheets
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TRANS-EXCISION-SPLICING RIBOZYME
AND METHODS OF USE

its RNA target, it is released from that RNA to search for
another target and can repeatedly bind and cleave neW targets.
A catalytic RNA that can excise a speci?c RNA sequence

RELATED APPLICATIONS

out of a larger RNA (the trans-excision-splicing reaction),
although not previously discovered or engineered, Would be
very useful as a biochemical tool and also as a potential neW

This application is a divisional ofU.S. Ser. No. 10/730,261,

therapeutic strategy. For example, multiple turnover catalytic

?led on Dec. 9, 2003 now US. Pat. No. 7,211,661, Which in

RNAs, or riboZymes, With this activity couldbe used to excise
a disease-causing RNA region out of a native transcript, to

turn claims the bene?t of US. Provisional Application No.
60/431,965, ?led on Dec. 10, 2002, the disclosures of Which

remove a premature stop codon, or to restore a frameshift

Applications are incorporated by reference herein.

mutation, for example.

FIELD OF THE INVENTION

SUMMARY OF THE INVENTION

This invention relates generally to the ?eld of genetic
therapeutics. More particularly, the invention relates to a

In one aspect of the invention there is provided a trans

excision-splicing riboZyme comprising at least tWo recogni

trans-excision-splicing riboZyme having adaptable sequence

tion elements that are complementary to a target sequence

recognition speci?city that provides a powerful tool for

Within a substrate, Wherein the target sequence is not comple
mentary to native recognition elements, Wherein at least one

genetic therapies.
BACKGROUND OF THE INVENTION

20

The discovery of catalytic RNA fundamentally changed
the course of science. The subsequent realiZation that cata
lytic RNAs could be tailored to suit individual needs has been

nothing less than inspiring. Indeed, the past ten years has seen
the creative development of numerous RNA catalysts. Con

substrate created by the excision to an 00G of the 3' end of the
25

currently, the diversity of applications for these catalytic
RNAs has been escalating. For example, catalytic RNAs are

otide sequence encoding a trans-excision-splicing riboZyme

vention of diseases, and for use as biochemical tools. As We
30

more tractable.

RiboZymes are RNA molecules having an enZymatic activ
35

separate RNA molecules in a nucleotide base sequence-spe
ci?c manner. Such enZymatic RNA molecules can be targeted

achieved in vitro. Kim et al., 84 Proc. Natl. Acad. Sci. USA
40

50

said riboZyme possessing catalytic activity against a target
RNA sequence present in said host cell,
55

60

Wherein the riboZyme catalyZes a speci?c excision of the
target RNA sequence and splices the 5' end of the substrate
created by the excision to an 00G of the 3' end of the substrate
created by the excision.
The folloWing de?nitions are used herein.
RiboZyme: An RNA molecule that inherently possesses cata

lytic activity.

target RNA. Thus, the enZymatic nucleic acid ?rst recogniZes
and then binds a target RNA through complementary base
pairing, and once bound to the correct site, acts enZymatically
to cut the target RNA. Strategic cleavage of such a target RNA
Will destroy its ability to direct synthesis of an encoded pro
tein. After an enZymatic nucleic acid has bound and cleaved

sequence.
In another aspect of the invention there is provided a
method for deleting an undesired genetic sequence from a

host cell in vivo, said method comprising:
(1) providing the riboZyme of the invention to the host cell,

RNA molecules) under physiological conditions. In general,
enZymatic nucleic acids act by ?rst binding to a target RNA.
Such binding occurs through the target binding portion of an
enZymatic nucleic acid Which is held in close proximity to an
enZymatic portion of the molecule that acts to cleave the

(2) providing a substrate comprising the target sequence to
the reaction mixture; and

(3) catalyZing the trans-splicing-excision of the target

neW targets.

Six basic varieties of naturally-occurring enZymatic RNAs

the substrate created by the excision.
Also provided are host cells transfected With the poly
nucleotide molecule.
In yet another aspect of the invention there is provided a
method for in vitro trans-splicing-excison of a target
sequence, comprising the steps of:
(1) providing the riboZyme of the invention in a trans

splicing reaction mixture;
45

and cleaved its RNA target it is released from that RNA to
search for another target and can repeatedly bind and cleave

are knoWn presently. Each can catalyZe the hydrolysis of
RNA phosphodiester bonds in trans (and thus can cleave other

least one of said recognition elements stabiliZes binding of
the riboZyme to a trans-excision splicing (TES) reaction inter
mediate product and Wherein the riboZyme catalyZes a spe
ci?c excision of the target sequence and splices the 5' end of
the substrate created by the excision to an 00G of the 3' end of

to virtually any RNA transcript, and e?icient cleavage

8788, 1987; Haseloff and Gerlach, 334 Nature 585, 1988;
Cech, 260 JAMA 3030, 1988; and Jefferies et al., 17 Nucleic
Acids Research 1371, 1989.
RiboZymes act by ?rst binding to a target RNA. Such
binding occurs through the target RNA binding portion of a
riboZyme, Which is held in close proximity to an enZymatic
portion of the RNA that acts to cleave the target RNA. Thus,
the riboZyme ?rst recogniZes and then binds a target RNA
through complementary base-pairing, and once bound to the
correct site, acts enZymatically to cut the target RNA. Strate
gic cleavage of such a target RNA destroys its ability to direct
synthesis of an encoded protein. After a riboZyme has bound

comprising at least tWo recognition elements that are comple
mentary to target sequence Within a substrate other than that

complementary to native recognition elements, Wherein at

novel and effective RNA catalysts is becoming more and

ity, Which enables the riboZyme to repeatedly cleave other

substrate created by the excision.
In another aspect of the invention there is provided a poly
nucleotide molecule comprising a riboZyme expression cas
sette that is capable of being stably inserted into a host, the
cassette comprising a promoter operably-linked to a nucle

being developed for detection protocols, for therapeutic inter
continue to exploit the steadily increasing knowledge base of
RNA structure, folding, and catalysis, designing and applying

of said recognition elements stabiliZes binding of the
riboZyme to a trans-excision splicing (TES) reaction interme
diate product, and Wherein the riboZyme catalyZes a speci?c
excision of the target sequence and splices the 5' end of the

Trans-splice: A form of genetic manipulation Whereby a
nucleic acid sequence of a ?rst polynucleotide is colinearly
65

linked to or inserted colinearly into the sequence of a second
polynucleotide, in a manner that retains the 3'-5' phosphodi

ester linkage betWeen such polynucleotides. By “directed”

US 7,776,835 B2
3

4

trans-splicing or “substrate-speci?c” trans-splicing is meant a

ground, SEQ ID NO: 1 0). In the trans-excision-splicing reac

trans-splicing reaction that requires a speci?c specie of RNA

tion, the bridging region (White lettering) is excised and the 5'

as a substrate for the trans-splicing reaction (that is, a speci?c

if the riboZyme is designed to be directed against a target

and 3' regions of the substrate (black lettering) are subse
quently spliced together. Note that PI, P9.0, and P10 are
helices that result from the recognition elements REl, RE2,
and RE3 base pairing With the substrate. The large bold

sequence present in a related set of RNAs.

arroWs indicate the sites of catalysis for the ?rst (left) and

Target sequence: A nucleic acid molecule, e.g., RNA, that is
a substrate for the catalytic activity of a riboZyme of the

The 5' uridine and 3' guanosine are circled. The riboZyme
bases are numbered according to that for the R carinii intron

specie of RNA in Which to splice the transposed sequence).
Directed trans-splicing may target more than one RNA specie

second (right) step of the trans-excision-splicing reaction.

invention.

(Testa, S. M., Haidaris, C. G., Gigliotti, E, & Turner, D. H.

Expression Cassette: A genetic sequence that provides

(1997) Biochemistry 36, l5303-l53l4.l3, incorporated

sequences necessary for the expression of a riboZyme of the
invention.

herein in its entirety). 2B). Simpli?ed diagrams of various
substrates base pairing With various riboZymes. Only the

Stably: By “stably” inserting a sequence into a genome is

recognition element sequences are shoWn for the riboZymes.
The dashed line indicates a normal phosphodiester bond
betWeen the adjoining sequences. i) The l2-mer substrate

intended insertion in a manner that results in inheritance of

such sequence in copies of such genome.

Operable linkage: An “operable linkage” is a linkage in Which
a sequence is connected to another sequence (or sequences) in
such a Way as to be capable of altering the functioning of the

20

(SEQ ID NO:7) binding to rP-8/4x (SEQ ID NO: 1 1). ii) The
l0-mer substrate (SEQ ID NO:8) binding to rP-8/ 4x (SEQ ID
NO:1 1). iii) The 38-mer Myotonic Dystrophy substrate (SEQ
ID NO:l2) binding to the rP8/4x-MD Myotonic Dystrophy

sequence (or sequences). For example, by operably linking a

riboZyme (SEQ ID NO:l3).

riboZyme encoding sequence to a promoter, expression of the
riboZyme encoding sequence is placed under the in?uence or

FIG. 3. The Trans-Excision-Splicing Reaction using the R
carinii system. The Trans-Excision-Splicing (TES) Reaction

control of that promoter. TWo nucleic acid sequences, such as

25

Using the R carinii System. A) Polyacrylamide gel shoWing

sequence at the 5' end of the encoding sequence, are said to be

substrates and products of the TES reaction using 166 nM
rP-8/4x riboZyme and 1.33 nM substrate at 7 mM MgCl2

operably linked if induction of promoter function results in
the transcription of the riboZyme encoding sequence and if

The reaction using the 36-mer substrate is diagrammed on the

a riboZyme encoding sequence and a promoter region

the nature of the linkage betWeen the tWo sequences does not

(36-mer) and 10 mM MgCl2 (l0-mer and l2-mer) at 440 C.
30

left (SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:15).

(1) result in the introduction of a frame-shift mutation, (2)

The regions of the substrate that bind to the riboZyme’s rec

interfere With the ability of the expression regulatory

ognition elements (labeled REl (SEQ ID NO: 15), RE2, and

sequences to direct the expression of the riboZyme. Thus, a
promoter region Would be operably linked to a nucleic acid
sequence if the promoter Were capable of effecting the syn
thesis of that nucleic acid sequence.

RE3) are underlined. All reactions in the presence (+) and
absence (—) of the rP-8/4x riboZyme Were subjected to the
35

substrate (9-mer product), and a l0-mer substrate (9-mer

Native target sequence/Non-native target sequence: Native
target sequence of a riboZyme is that polynucleotide sequence

Which is recogniZed, bound and reacted by Wild-type (native)

40

riboZymes. Non-native target sequence is sequence Within a
substrate that is not bound by Wild type riboZyme and conse
quently native riboZyme does not react With non-native target

the 36-mer starting material. B). Graphs of TES reactions
45

BRIEF DESCRIPTION OF THE DRAWINGS

strate. All reactions Were run as above except for the changing

50

shoWs the average of tWo independent assays.

55

FIG. 4. Sequencing of Trans-Excision-Splicing Products.
For each system, a chemically synthesiZed version of the
expected product Was sequenced and run adjacent to the
isolated excision product. Left: the R carinii l6-mer product
that results from treating the 36-mer substrate With the rP-8/

RNAs are represented by gray lines, the 5' and 3' exons and
mimics are black lines, and the bridge (excised region) is a
dotted line. The circle in the 5' exon represents a uridine and
the circle in the 3' exon represents a guanosine. The intron

inherently contains all the required activities for the trans
excision-splicing reaction. REl, RE2, and RE3 are three rec
ognition elements that the catalytic RNAs may use to base
pair With their substrates (RE3 is also referred to as the IGS,
or Internal Guide Sequence.). It is likely that RE2 and/ or RE3
do not bind the substrate until after the ?rst reaction step. In

except for the changing variable. The TES product is repre
sented by ?lled circles and the 5' cleavage product by open
circles. C). Graphs of TES reactions using the l0-mer sub

variable. The TES product is represented by ?lled triangles
and the 5' cleavage product by open triangles. Each graph

FIG. 1. The Group I Intron Self-Splicing (111: left) and

Trans-Excision-Splicing Reactions (1b: right). The catalytic

product). See FIG. 2 for the sequence of these substrates. The
6-mer lane shoWs a synthetic control for the 5' cleavage prod
ucts, the l6-mer lane shoWs a synthetic control for the l6-mer
TES product, and the ‘OH lane shoWs an alkaline digest of
using the 36-mer substrate. All reactions Were run as above

sequence. Non-native target sequence can occur as a result of

mutation, for example.

same incubation conditions. TES reactions Were conducted

using a 36-mer substrate (to give a l6-mer product), a l2-mer

4x riboZyme. Right: the Myotonic Dystrophy l0-mer product

60

addition, at least With the rP-8/4x riboZyme used herein, the
guanosine cofactor is not required for initiation of the ?rst

that results from treating the 38-mer substrate With the rP-8/
4x-MD riboZyme. The dotted line represents the neWly cre
ated splice junctionbetWeen the 5' and 3' ends of the substrate.
Nuclease T1 is speci?c for guanosine, U2 for adenosine, and
CL-3 primarily for cytidine. The ‘OH lane shoWs an alkaline

rP-8/4x (uppercase lettering, SEQ ID NO:9), binding to the

digest of the starting material, and the lanes labeled ‘Start’
shoW the starting material.
FIG. 5. Competition TES Reactions. Polyacrylamide gel
shoWing substrates and products of TES reactions using 166
nM rP-8/4x, 7 mM MgCl2, and 440 C. ‘Radiolabeled sub

36-mer substrate (loWercase lettering With a gray back

strate’ refers to the length of the radiolabeled substrate at 1.33

catalytic step.
FIG. 2. The rP-8/4x and rP-8/4x-MD RiboZymes Base

Pairing With Various Substrates. 2A) The R carinii riboZyme,

65

US 7,776,835 B2
5

6

nM ?nal concentration and ‘cold substrate’ refers to the
length of the non-radiolabeled substrate. The ?nal concentra
tions of the cold substrates are 1.33 nM for the 36-mer, and
66.5 nM (50><) or 665 nM (500><) for the 7-mer, Which is

recognition elements are maintained, this riboZyme can
excise the bridging sequence and splice the 5' and 3' ends of

the substrate together. A simple diagram of this trans-exci
sion-splicing reaction is shoWn in FIG. 1b. This reaction Was

tested using a riboZyme, rP-8/4x, from the opportunistic

r(GUGCUCU) (SEQ ID NO: 16). The tWo substrates for each
reaction Were added simultaneously. Lanes designated in the

pathogen Pneumocyslis carinii. In FIG. 2A it is shoWn that

this riboZyme catalyZes the trans-excision-splicing reaction

?rst box are length controls, the second box shoWs the 5' exon
competition assay, the third box shoWs an alkaline digest of

using a synthetic substrate Which is complementary to the
native recognition elements of the rP-8/4x riboZyme. More

the 36-mer starting material, and the fourth box shoWs the 3'

over, as little as a single nucleotide can be excised.

exon competition assay.

In order for this reaction to be useful, hoWever, the
riboZyme recognition elements have to be mutable, such that

FIG. 6. The TES Reaction Using the DMPK Model Sys

tem. A) Polyacrylamide gel shoWing substrates and products

the riboZyme can be targeted to bind With and react on non

of the TES reaction using 166 nM rP-8/4x-MD riboZyme,
1.33 nM substrate, 13 mM MgCl2, and 440 C. The reaction
using the 38-mer DMPK mimic is diagrammed on the left

native sequences. Using a group I intron-derived riboZyme

from Telrahymena lhermophila, the sequence of RE1 (also
referred to as the IGS, or Internal Guide Sequence) Was
mutated and the resultant riboZyme then bound to a neW,

(SEQ ID NO:12, SEQ ID NO:17 and SEQ ID NO:18). The
regions of the substrate that bind to the riboZyme’s recogni
tion elements are labeled RE1 (SEQ ID NO:18), RE2, and
RE3. All reactions in the presence (+) and absence (—) of the
rP-8/4x-MD riboZyme Were subjected to the same incubation
conditions. TES reactions Were conducted using the 38-mer
substrate (to give a 10-mer product). The 6-mer lane shoWs a

complementary substrate (Murphy, F. L. & Cech, T. R. (1989)
Proc. Natl. Acad. Sci. USA. 86, 9218-9222; Been, M. D. &
20

synthetic control for the 5' cleavage products, the 10-mer lane
shoWs a synthetic control for the 10-mer TES product, and the
iOH lane shoWs an alkaline digest of the 38-mer starting
material. The lanes labeled 36 are TES reactions using the
rP-8/4x-MD riboZyme With the 36-merR carinii substrate (at
13 mM MgCl2), and the lane labeled 38 (lane 0) is a reaction
using the rP-8/ 4x riboZyme With the 3 8-mer DMPK mimic (at
7 mM MgCl2). In these cases, no reaction occurs. B). Graphs
of TES reactions using the 38-mer substrate and rP-8/4x-MD.
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Huntington’s disease, Fragile X, and Myotonic Dystrophy

repeat sequences. For Myotonic Dystrophy, the expansion is
in the 3' UnTranslated Region [3' UTR] of a serine-threonine

protein kinase gene [the DMPK gene], Whose expression
induces the expression of skeletal muscle speci?c genes. The

reaction Was carried out for 90 minutes using 166 nM
riboZyme and 1 .33 nM radiolabeled 13 -mer substrate at either
0 mM or 10 mM MgCl2 at 44 degrees C., either in the presence
(+) or absence (—) of330 nM GMP. FIG. B is a diagram ofthe

disease state of Myotonic Dystrophy, Which is the most com
mon form of adult onset Muscular Dystrophy, typically has
much more than 35 CUG repeats, While unaffected individu

als typically have less than 15 repeats. The greater the number
of repeats, the more severe the affects of the disease. More

over, strong experimental evidence indicates the disease
45

stems directly from the RNA repeats, and not to any affected

coding potential of the parent DNA. In fact, the Myotonic

Dystrophy triplet-expansion and recently discovered quadru

diate (CUCUCU) (SEQ ID NO:21) is represented by open

plet-expansion diseases have the repeat sequences Within

circles. All reactions Were run as above except for the chang
ing variable. Each curve represents the average of tWo inde

pendent assays. Standard deviation for all points Was less than
10%. For clarity the graphs use different scales.

larger RNA, including triplet-expansion diseases such as
(BoWater, R. P. & Wells, R. D. (2001) Prog. Nucleic Acid Res.
Mol. Biol. 66, 159-202). Patients affected With these diseases
have an RNA that is present in normal individuals, except that
embedded Within it is an abnormally high number of tandem

variable. The TES product is represented by ?lled squares and
the 5' cleavage product by open squares.

TES reaction (SEQ ID NO:19 and SEQ ID NO:20). The
excised G of SEQ ID NO:19 is in bold lettering. FIG. 7C
shoWs tWo graphs of TES reactions using the 13-mer sub
strate and the A-L-21 Sca riboZyme (Telrahymena). The TES
product is represented by the ?lled circles and the 5' interme

splicing riboZymes that can replace the 3' end of mutant
transcripts With corrected versions (Sullenger, B. A. & Cech,
T. R. (1994) Nature 371, 619-6; Lan, N., HoWrey, R. R, Lee,
S. W., Smith, C. A., & Sullenger, B. A. (1998) Science 280,
1 593 -1 5 96).
Trans-excision-splicing riboZymes are ideal for treating
genetic diseases for Which the causative affects may be ame
liorated by the excision of an internal RNA segment out of a

All reactions Were run as above except for the changing

FIG. 7. TES reactions using tWo different Telrahymena
riboZymes. FIG. 7A is a polyacrylamide gel shoWing sub
strates, intermediates, and products of the TES reaction. The

Cech, T. R. (1 986) Cell 47, 207-216; Zaug,A. 1., Been, M. D.,
& Cech, T. R. (1986)Nalure 324, 429-433). This property has
been exploited for, among other purposes, designing trans
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non-coding regions, so their effects are not due to the synthe
sis of mutant proteins. A neW class of riboZymes that can

speci?cally excise these expanded RNA repeats from the
transcripts could aid in the development of much needed

therapeutics against these types of diseases.
The rP-8/4x riboZyme Was re-engineered to test the poten
tial to alter the sequence speci?city of trans-excision-splicing

DETAILED DESCRIPTION OF THE INVENTION

The inherent binding and catalytic activity of group I
intron-derived riboZymes can be exploited to catalyZe the

55

from a Myotonic Dystrophy DMPK small model system in

vitro. The resultant riboZyme excises the triplet expansion

trans-excision-splicing reaction. FIG. 1a shoWs a simple dia
gram of a typical group I intron-catalyZed self-splicing reac

region, and in a sequence speci?c manner. That trans-exci

sion-splicing riboZymes can be re-engineered to target and

tion. There are three base pairing contacts that the intron uses

act upon predetermined sequences demonstrates a general
usefulness for these riboZymes as biochemical tools and

to hold and position its 5' and 3' exons for subsequent cataly

sis. We have termed these the riboZyme recognition elements,

therapeutics.

or RE1 , RE2, and RE3. Physically removing the intramolecu
lar exons from the intron creates a riboZyme that has the

R carinii Group I Intron RiboZyme CatalyZes the Trans

Excision-Splicing Reaction.

ability to bind and catalyZe reactions using exogenous sub
strates that contain 5' and 3' exon sequences (Zaug, A. J. &

riboZymes to bind and excise the triplet expansion region

65

A riboZyme derived from a P carinii group I intron cata

Cech, T. R. (1986) Science 231, 470-475.). If the 5' and 3'

lyZes a previously unreported excision-splicing reaction on

exon sequences are connected With a bridging sequence and

an exogenous substrate. This trans-excision-splicing reaction

US 7,776,835 B2
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takes advantage of the catalytic abilities of this riboZyme.
First, rapid and e?icient sequence-speci?c cleavage of a des
ignated substrate occurs in a guanosine independent fashion,
as previously reported (Testa, S. M., Haidaris, C. G., Gigliotti,
F., & Turner, D. H. (1997) Biochemistry 36, 15303-15314.).

sequences and lengths (1, 3, 20, and 28 nucleotides) have
been excised, indicating that the 3' G in the bridging region
might be the only potential sequence requirement for the

Second, the resultant 5' cleavage product can splice to a
sequence that binds the 3' end of the riboZyme (Inoue, T.,

Within the Myotonic Dystrophy substrate doesn’t prohibit the
reaction. In addition, each riboZyme only acts upon its des

Sullivan, F. X., & Cech, T. R. (1985) Cell 43, 431-437) (FIG.
1B). These activities Were exploited by designing a synthetic

ignated target, even though the RBIs in both riboZymes are
50% identical, giving a further indication of the high level of

substrate that contains Within it the sequences required for

sequence speci?city of this reaction. Although the MgCl2
concentration required for maximum activity is different for
the tWo riboZymes (7 and 13 mM), they both are active
throughout the same general MgCl2 concentration range
(data not shoWn), Which is beloW that required (15 mM) for
maximum activity for the R carinii group I intron self-splic
ing reaction in vitro.
The ability to catalyZe TES reactions is inherent to Group

excised segment. Structure might even be tolerated Within the
excised region, as the someWhat structured CUG repeat

each catalytic event, separated by an internal bridging
sequence (FIG. 2A). As seen in FIG. 3, the engineered
riboZyme catalyZes the speci?c excision of the bridge
sequence and splices the 5' and 3' ends of the substrate back
together. Even though there are 1 8 other uridines that could be
sites of 5' cleavage and 4 other guanines that could be sites of

3' splicing, only one trans-excision-splicing product is gen
erated. Apparently, the riboZyme recognition elements that
de?ne the individual catalytic steps are sequence speci?c.
That the riboZyme can catalyZe this reaction is surprising in

I introns. To determine Whether other riboZymes can catalyZe
TES reaction, a TeZrahymena-containing L-21 ScaI plasmid
20

that the relatively long bridging region could be expected to

Was lineariZed With ScaI, run-off transcriptions Were per

formed, and the riboZyme Was puri?ed as described by Testa

sterically hinder the binding of the substrate to the catalytic

et al. (Biochemistry, (1997) 36:15303-15314). TES reactions

core of the riboZyme or hinder the required conformational

Were run in a variety of standard buffers and conditions rou

rearrangement betWeen the tWo catalytic steps (Cech, T. R.,
Herschlag, D., Piccirilli, J. A., & Pyle, A. M. (1992) J. Biol.
Chem. 267, 17479-17482; and 39. Jaeger, L., Michel, F. &
Westhof, E. (1996) in Catalytic RNA, eds. Eckstein, F. &

tinely used for riboZyme reactions. The reactions Were also
25

cases, the ?rst step of the reaction Was the only reaction step
that Was detected.

Lilley, D. (Heidelberg, Germany), Vol. 10, pp. 1-17). Perhaps
this accounts for over 50% of the substrate only undergoing

the ?rst catalytic step (see FIG. 3). In addition, like other

30

riboZymes, the R carinii riboZyme binds its 5' exon sequences
orders of magnitude tighter than its 3' exon sequences, Which
alloWs time for 3' end dissociation prior to the second cata

Therefore, the Telrahymena riboZyme Was modi?ed to con
tain an RE3 region in order to stabiliZe binding of the
35

another substrate. Since spontaneous 3' splice site hydrolysis
is essentially non-existent and only an insigni?cant amount of

excised from the band and sequenced, and shoWn to be the

5' exon-bridge 26-mer product (Which Would be a side reac
40

mechanism occurs to a signi?cant extent.
The R carinii riboZyme can excise as little as one nucle

P90 helix. Therefore, the RE2 interaction, although perhaps

45

sequence binds to a mutant RNA transcript, cleaves the

mutant transcript, and replaces the 3' end of the mutant tran
50
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script With the normal ‘corrected’ version. While trans-splic
ing can correct mutant RNA, it is single-turnover, it exploits
only the RBI molecular interaction, and the riboZyme must be
covalently attached to the neW, corrected transcript. In con

trast, the trans-excision-splicing reaction is potentially mul
tiple turnover; it exploits the RBI, RE2, and/or RE3 molecu
lar interactions; and it excises an internal segment from
Within a larger RNA. Nevertheless, these tWo complementary

The sequence speci?city of the P carinii riboZyme can be
altered. Altering the recognition elements of the R carinii

riboZyme changes the sequence speci?city of the trans-exci

Comparison With the Trans-Splicing Reaction. The trans
excision-splicing reaction of the invention is fundamentally
different from the trans-splicing reaction previously reported
(Sullenger, B. A. & Cech, T. R. (1994) Nature 371, 619-622.),
Whereby a riboZyme covalently attached to a normal RNA

bene?cial, is not required to establish a sequence speci?c
interaction. In addition, the 12-mer and 10-mer substrates
lead to approximately 50% more product as compared With
the 36-mer substrate. There are many possible explanations

for this, including the longer bridge of the 36-mer substrate
partially interfering With the substrate’s ability to bind the
recognition elements.

expected TES product. These results demonstrate that the
ability to catalyZe TES reactions is a general property inher
ent to group I introns.

otide. The P carinii riboZyme excises as little as a single

nucleotide, and in a sequence-speci?c manner. Apparently,
there is no loWer limit to the siZe of the region being excised.
That the same approximate yield is obtained regardless of
Whether the 12-mer (39%) and 10-mer (36%) substrate is
used suggests that the role of forming the P90 helix is not
large in this case, as the 10-mer lacks the ability to form the

riboZyme to the ’3 exon reaction intermediate. The results are

shoWn in FIG. 6. The reaction using the stabiliZed riboZyme
generates a product band of the expected siZe (a 12-mer
product from a 13-mer substrate). The product band Was

that the 5' exon of one substrate could ligate to the 3' exon of

tion of this catalytic event) is produced, it is unlikely that this

The lack of a full-length, second-step reaction product
suggests that the second step may be inef?cient or problem
atic With this riboZyme. Our previous studies of the R carinii
riboZyme had demonstrated that 3' intermediate disassocia

tion results in signi?cantly reduced second-step yields.

lytic step. Nevertheless, a signi?cant amount of trans-exci

sion-splicing product is generated. Another consideration is

run in the presence and absence of the PG cofactor. In all

reactions share many similarities and so the Wealth of knoWl

edge already reported for the trans-splicing reaction is appli
60

cable to the trans-excision-splicing reaction.

sion-splicing reaction. While it Was knoWn that RE1 could be

Implications for Myotonic Dystrophy. The rP-8/4x

modi?ed in reactions mimicking the ?rst step of the self
splicing reaction, it Was previously not knoWn that all three

riboZyme can be redesigned to speci?cally excise the entire

elements are mutable. That these recognition elements com

pletely specify binding and reactivity indicates that they are
the primary determinants of speci?city betWeen the riboZyme
and its substrate. In addition, bridging regions of different
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triplet expansion region of a mimic of the Myotonic Dystro
phy transcript, implicating such riboZymes as neW types of
potential Muscular Dystrophy therapeutics. As a practical
matter, cutting out this entire region may or may not restore
proper function to the transcript, as normal individuals typi
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cally have at least 5 repeats. Similar multiple turnover
riboZymes, however, can be designed to target the repeats

providing a DNA copy of the riboZyme on a plasmid that is

themselves to successively reduce expansion lengths.
General Therapeutic Implications. Unfortunately, nature

invention is inserted into the host’s chromosome as part of an

DNA copy of the riboZyme into the host’s chromosome, or by

stably retained by the host cell. Preferably the riboZyme of the

has afforded a huge number ofRNA-mediated mutations that

expression cassette, Which provides transcriptional regula

predispose individuals to disease. NeW therapeutic strategies

tory elements that control the transcription of the riboZyme in
the host cell. Such elements may include, but not necessarily

to combat these diseases are needed. That the recognition
elements of the rP-8/ 4x riboZyme canbe modi?ed and the siZe
and sequence of the excised region do not appear to have

ment, and a transcriptional terminator signal. Polyadenyla

limitations suggest that trans-excision-splicing riboZymes

tion is not necessary as the riboZyme is not translated.

may be generally useful as therapeutics against many such

Expression of a riboZyme Whose coding sequence has been
stably inserted into a host’s chromosome is controlled by the
promoter sequence that is operably linked to the riboZyme

be limited to, a promoter element, an enhancer or UAS ele

diseases. For example, excising speci?c sequences could
remove premature stop codons, restore altered reading

coding sequences. The promoter that directs expression of the
riboZyme may be any promoter functional in the host cell,

frames, or remove insertion mutations that affect transcrip

tion and translation regulation.
Trans-excision-splicing riboZymes are thought to have tWo

prokaryotic promoters being desired in prokaryotic cells and

sequence preferences. The ?rst is a uridine at the 5' cleavage
site (although a cytidine might also Work) and the second is a

eukaryotic promoters in eukaryotic cells. A promoter is com
posed of discrete modules that direct the transcriptional acti

guanosine at the 3' splice site (FIG. 2A). Therefore, there are
three simple targeting strategies to consider. First, a riboZyme

20

can be designed that targets a uridine 5' to any particular
mutation and a guanosine 3' to this mutation, as is the case in

vation and/ or repression of the promoter in the ho st cell. Such
modules may be mixed and matched in the riboZyme’s pro
moter so as to provide for the proper expression of the

riboZyme in the host. A eukaryotic promoter may be any

the Myotonic Dystrophy model system described here. It

promoter functional in eukaryotic cells, and especially may

should be noted that if more than an insertion mutation is

be any of an RNA polymerase I, II or III speci?cally. If it is
desired to express the riboZyme in a Wide variety of eukary
otic host cells, a promoter functional in most eukaryotic host

excised the neW transcript might not function normally. Sec

25

ond, a mutation that results in a neW guanosine canbe targeted

as the 3' splice site. The above strategies Will also target
normal transcripts for at least the ?rst step of the reaction, so
these strategies should be designed With care. Third, a muta
tion that results in a neW uridine can be targeted as the 5'

cells should be selected, such as a rRNA or a tRNA promoter,

30

cell-speci?c (or tissue-speci?c) promoter element that is

cleavage site. This resultant riboZyme Would not attack the
normal transcript, but Would perform both steps on the mutant
transcript. Since point mutations that result in premature ter
mination codons often involve a neW uridine (all termination

codons begin With uridine), hundreds of distinct mutations

35

could be speci?cally targeted. Therefore, many options for
targeting are possible, Which expands the potential usefulness
of these riboZymes. The general strategy of targeting muta
tions at the RNA level, hoWever, should be considered a
potential treatment rather than a potential cure, as mutant

40
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The

applicability

contain at least tWo modi?able REs. In a preferred embodi

ment, the riboZyme contains modi?ed RBI and RE3. Which
alloWs the riboZyme to target designated substrates at the

of trans-excision-splicing
50

region that is involved in a common form of Muscular Dys
trophy in a small model system in vitro. Therefore, trans
excision-splicing riboZymes are a neW class of riboZymes that

permits potential biochemical and therapeutic strategies not
before possible.

these pseudoknot structures entirely through tertiary interac
tions. In contrast, the riboZymes used in the present invention

sequence speci?c and as little as a single nucleotide can be

excised.

I intron riboZymes that lack both of the exons and the IGS can

catalyZe a guanosine cofactor-mediated TES-like reaction
upon binding pseudoknot structured substrates, Which creates
the in trans equivalent of the P1 and P10 helices (P9.0 helix
formation Was not required). The riboZymes target and bind

obtained from different organisms can catalyZe this neW

riboZymes to treat disease has been demonstrated by design
ing a riboZyme that speci?cally removes the triplet expansion

functional only in that cell or tissue type should be selected.
The trans-splicing reaction is chemically the same Whether
it is performed in vitro or in vivo. HoWever, in vivo, the
presence of the target and the riboZyme Will suf?ce to result in
trans-splicing, since cofactors are usually already present in
the host cell.

It has been previously reported that, at high MgCl2 (10-100
mM) and temperature (550 C. to 65° C.), Telrahymena group

RNA transcripts Will continue to be produced.
As shoWn herein, group I intron-derived riboZymes

trans-excision-splicing reaction. In addition, the sequence of
the riboZyme can be easily manipulated such that it targets
and acts upon desired substrates, including those of medical
importance. The reactions themselves appear highly

or the promoter for a Widely expressed mRNA such as the
promoter for an actin gene, or a glycolytic gene. If it is desired
to express the riboZyme only in a certain cell or tissue type, a

level of simple base pairing. Furthermore, the TES reactions
using the R carinii and Telrahymena riboZymes do not
require a guanosine cofactor, and optimally occur at a loWer

MgCl2 concentration (7-13 mM) and temperature (440 C.).
Sullenger and Cech ((1994) Nature 371, 619-622.) previ
55

ously reported that Telrahymena group I intron riboZymes
that lack a 5' exon, but contain an endogenous non-native 3'

The riboZymes of the invention can be introduced into and

exon, catalyZe the covalent attachment of the endogenous 3'

expressed in a host cell. Transcription of the riboZyme of the

exon to mutant transcripts in such a Way as to replace the 3'

end of mutant transcripts With normal ‘corrected’ versions.

invention in a host cell occurs after introduction of the

riboZyme gene into the host cell. If the stable retention of the
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riboZyme by the host cell is not desired, the riboZyme may be
chemically or enZymatically synthesiZed and provided to the
host cell by mechanical methods, such as microinjection,

turnover, and repairing mutations distant from the 3' end of

liposome-mediated transfection, electroporation, calcium
phosphate precipitation, or the like. Alternatively, When
stable retention of the gene encoding the riboZyme is desired,
such retention may be achieved by stably inserting at least one

While trans-splicing can repair RNA, it exploits only the RBI
molecular interaction, the riboZymes must be covalently
attached to the repaired half of the transcript, it is single

65

long transcripts could be problematic. In contrast, the TES
reaction exploits multiple molecular interactions (RE1, RE3,
and perhaps RE2), TES riboZymes excise an internal segment
from Within RNA substrates, the reaction is potentially mul
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tiple turnover, and the position of the mutations Within the
transcript is not a limiting factor. Moreover, that under the
conditions used in this report, little (if any) turnover Was

each NTP, 1.25 mg/mL BSA, and 4 pL of T7 RNA poly
merase (100 units/uL) and Was incubated for tWo hours at 37°

C. The resultant RNA Was puri?ed using QIAGEN-tip 100
anion-exchange columns. First, each column Was equili
brated With 4.0 mL of Buffer I (750 mM NaCl, 50 mM MOPS

observed.

Example 1

(pH 7.0), 15% ethanol, and 0.15% Triton X-100). Second, the
transcription reactions Were loaded onto the column and the
column Was Washed With 7.0 mL of Buffer I. Third, the

0ligonucleotide synthesis and preparation. DNA oligo
nucleotide primers Were purchased from Integrated DNA
Technologies (Coralville, IoWa), and Were used Without fur
ther puri?cation. RNA oligonucleotides Were purchased from
Dharmacon Research Inc. (Boulder, Colo.) and deprotected

Were dissolved in Water and quanti?ed using a Beckman

folloWing the manufacturer’s protocol. The oligoribonucle

UV-VIS DU-650 spectrophotometer.

transcripts Were eluted using 4.0 mL of Buffer II (1.0 M NaCl,
50 mM MOPS (pH 7.0), and 15% ethanol). FolloWing an
isopropanol and then an ethanol precipitation, the samples

otides Were 5' end radiolabeled and puri?ed via gel electro

Trans-excision-splicing reactions. Reactions Were con

phoresis as previously described (Testa, S. M., Haidaris, C.
G., Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36,

ducted in H><Mg buffer consisting of 50 mM Hepes (25 mM
Na”), 135 mM KCl, and x mM MgCl2 (listed in the ?gures) at
pH 7.5. The trans-excision-splicing reactions Were optimiZed

15303-15314.). The RNA products Were extracted from the
gel slice by stirring for one hour With a sterile stir-bar in 1.5

mL elution buffer containing 10 mM Tris (pH 7.4), 250 mM
NaCl, and 1 mM EDTA. Gel particulate Was removed via
centrifugation, and the solution Was evaporated to a ?nal

20

riboZymes, 7 mM MgCl2 for rP-8/4x, and 13 mM MgCl2 for
rP-8/4x-MD, although a signi?cant amount of each product

oligoribonucleotide concentration of approximately 8 nM.
Plasmid construction and synthesis. The R carinii

Was obtained at 37° C. at both 7 and 13 mM MgCl2 for each

riboZyme plasmid precursor, P-8/4x, Was generated as previ

ously described (Testa, S. M., Haidaris, C. G., Gigliotti, E, &
Turner, D. H. (1997) Biochemistry 36, 15303-15314). The

25

appropriate temperature. Reactions using the rP-8/ 4x
riboZyme Were initiated by adding 1.0 pL of 8 nM radiola
30

recognition elements using the folloWing pairs of mutagenic
primers (underlined bases represent altered recognition ele

ci?c substrate or the 36-merR carinii substrate. The substrate

GAACCTCTATAGTGAGTCG3v (SEQ ID N011) and 5’CG
ID N012) for RE1 formation, 5vGGTATAGTCTEC
CTCTTTCGAAAG3v (SEQ ID N013) and 5vCTTTCGAAA
GAGGC_AAGACTATACC3v for RE2 (SEQ ID N014) forma
tion, and then 5vCGACTCACTATAQGTTCCCGAA
AGCGGC3v (SEQ ID N015) and 5vGCCGCTTTCGGGAA
C?TATAGTGAGTCG3v (SEQ ID N016) for RE3 forma

sequences and hoW they base pair With the riboZymes are
35

40

3MM CHR) and dried under vacuum. The bands Were visu
aliZed and quanti?ed on a Molecular Dynamics Storm 860

Phosphorimager.
45

(NH4)2S04, 20 mM Tris-HCl (pH 8.8), 2 mM MgS04, 0.1%
Triton X-100, and 0.1 mg/mL BSA (?nal volume 50 uL).
After an initial denaturation for 30 seconds at 95° C., the
50

C., Narang, M., Barcelo, 1., 0’Hoy, K., et al (1992) Science
255, 1253-1255). The ?rst step Was obtained from a plot of
the percent intermediate plus percent product formed versus
time, and the second step Was obtained from a plot of percent

buffer for 2 hours at 37° C. 3 pL of this mixture Was then used

product formed versus time. These observed rate constants
55

(QIAGEN; Valencia, Calif.). The resultant ?nal plasmid, P-8/
4x-MD, Was sequenced for con?rmation (ACGT, Inc; North
brook, Ill.). The plasmids Were lineariZed With Xba I, phenol/
chloroform extracted, and ethanol precipitated in preparation
for run-off transcription.

The observed rate constant, kobs, for the ?rst (5' cleavage)
and second (exon ligation) step of each reaction Was quanti
?ed (Testa, S. M., GryaZnov, S. M. & Turner, D. H. (1998)

Biochemistry 37, 9379-9385; Mahadevan, M., Tsil?dis, C.,
Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville,

plasmid Was then digested With 20 units Dpn I (Gibco BRL;
Rockville, Md.) in 5.7 pL of the manufacturer’s supplied
to transform E. coli DHSO. competent cells (Gibco BRL). The
vectors Were puri?ed using a QIAprep Spin Miniprep Kit

The products and reactants Were denatured for one minute at
90° C. and then separated on a 12% acrylamide/ 8 M urea gel.

The gel Was transferred to chromatography paper (Whatman

ampli?cation reaction comprising 25 ng parental plasmid, 2.5
units Pfu DNA polymerase (Stratagene; La Jolla, Calif.), and

mixture Was subjected to 15 cycles of 95° C. for 30 seconds,
500 C. for tWo minutes, and 68° C. for six minutes. Parental

shoWn in FIG. 2. In each case the substrates Were preincu

bated in the appropriate buffer (listed in the ?gures). After one
hour, the reactions Were terminated by adding an equal vol
ume of stop buffer (10 M urea, 3 mM EDTA, and 0.1><TBE).

tion. Each set of primers (15 pmol each primer) Was used in an
0.5 uM dNTPs in a buffer comprising 10 mM KCl, 10 mM

beled 36-mer, 12-mer, or 10-merR carinii-speci?c substrates
or the 38-mer Myotonic Dystrophy substrate. Reactions
using the rP-8/4x-MD riboZyme Were initiated by adding 1.0

uL of 8 nM radiolabeled 38-mer Myotonic Dystrophy-spe

ments as compared to P-8/4x)1 5‘CACGCCGCTTTCE

ACTCACTATAGAGGTTCCCGAAAGCGGCGTG3v (SEQ

riboZyme (data not shoWn). Prior to each reaction, 1.0 pmol of
riboZyme in 5.0 pL of the appropriate buffer Was preannealed
at 60° C. for ?ve minutes and then alloWed to sloW-cool to the

Myotonic Dystrophy-speci?c riboZyme plasmid precursor,
P-8/4x-MD, Was derived from the P-8/4x plasmid by site
directed mutagenesis. Brie?y, three successive rounds of
mutagenesis Were performed to modify each of the three

for the rP-8/4x and rP-8/4x-MD riboZymes over a MgCl2
concentration range of0 to 50 mM at 30° C., 37° C., and 44°
C. Maximum product formation occurred at 44° C. for both

re?ect the rate of chemistry and any requisite conformation
changes that occur.

Sequencing the trans-excision-splicing products. Products
obtained from the trans-excision-splicing reactions Were gel
60

Transcription. Both rP-8/4x and rP-8/4x-MD Were tran

puri?ed and sequenced by partial nuclease digestion using T1
(Epicentre; Madison, Wis.), U2 (Research Unlimited; Well
ington, NeW Zealand), and Cl-3 (Research Unlimited) RNA

scribed from their appropriate plasmid precursors essentially

nucleases. T1 reactions used 1.0><1 units T1 in 200 mM Tris

as previously described for rP-8/ 4x (Testa, S. M., Haidaris, C.

HCl (pH 7.5), Cl-3 reactions used 0.33 units Cl-3 in 200 mM
Tris-HCl (pH 7.5), and U2 reactions used 0.33 units U2 in 200

G., Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36,
15303-15314). A typical transcription reaction (40 pL) con
tained 1 ug lineariZed plasmid, 40 mM Tris-HCl (pH 7.4), 5
mM dithiothreitol, 5 mM spermidine, 5 mM MgCl2, 1.5 mM

65

mM Tris-HCl (pH 3.5). Sequencing reactions utiliZed
approximately 50 fmol of RNA and Were incubated for 10
minutes at 55° C. Immediately after adding an equal volume

US 7,776,835 B2
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of stop buffer to each reaction, aliquots Were loaded on a

product is generated. Apparently, the riboZyme recognition

13.5% polyacrylamide/8 M urea gel. In parallel With the

elements that de?ne the individual catalytic steps are
sequence speci?c. That the riboZyme can catalyZe this reac

above reactions, We enZymatically sequenced chemically
synthesized versions of the expected trans-excision-splicing

tion at all is surprising in that the relatively long bridging
region could be expected to sterically hinder the binding of

products for comparison.
To determine if the 3' product of the ?rst reaction step (5'

the substrate to the catalytic core of the riboZyme, or at least

cleavage) (FIG. 1B) is dissociating and then rebinding the

signi?cantly hinder the required conformational rearrange

same (or different) riboZyme before the second reaction step

ment betWeen the tWo catalytic steps. One or both of these

(exon ligation), TES reactions Were conducted for one hour in
7 mM MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM radiola
beled 36-mer substrate, and either 66.5 nM (50x) or 665 nM

might account for the majority (>50%) of the 36-mer sub
strate only undergoing the ?rst catalytic step, in contrast to
less than 10% only undergoing the ?rst step for the self
splicing reaction in vitro (15, 17). The lack of product break
doWn seen in the time dependence studies, hoWever, indicates

(500x) 3' exon mimic competitor r(GUGCUCU) (SEQ ID
NO: 16). The values reported are the average of six indepen
dent assays. Likewise, to determine if the 5' product of the

that the TES products themselves are not substrates for fur

?rst reaction step (5' cleavage) (FIG. 1B) is dissociating and
then rebinding the riboZyme before the second step (exon

ther reactions, although guanosine dependent 5' cleavage or

ligation), TES reactions Were conducted for one hr in 7 mM

riboZyme-mediated hydrolysis of the products could be a

MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM 36-mer non
radiolabeled substrate, and 1.33 nM radiolabeled 5' exon

factor in vivo.

mimic competitor r(AUGACU) (SEQ ID NO:15). In each

20

case the competitors Were added simultaneously With the
substrates.

ID NO:15) binds to the rP-8/4x riboZyme (Kd:5.2 nM at 37°
C.) three orders of magnitude more tightly than the 3' exon

Example 2
25

The R carinii group I intron riboZyme catalyZes the trans
excision- splicing reaction In order to test Whether a riboZyme
derived from a group I intron, and speci?cally one from R
30

native recognition element sequences (RE1, RE2, and RE3 in
FIG. 1b). These substrate sequences Were connected With a

bridge consisting of the ?rst four bases of the intron and 13
uridines (FIG. 2A). Uridines Where chosen because of their
relatively poor ability to form self-structures and the number
of uridines (13) Was chosen arbitrarily. Typical results at the

35

40

chemically synthesiZed version of the expected product. The
45

generating. The reaction also produced a band at six nucle
otides. This is a product of the ?rst step of the tWo-step

that a portion of the transcript undergoes only the ?rst step of

a 500-fold excess of cold competitor over substrate does not
55

signi?cantly reduce the amount of 16-mer product formed
(19.4%:2.3% versus 22.8%:3%, respectively). The small

60

amount of 10-mer product that is observed at 500-fold excess
competitor over substrate (but not 50-fold excess) is not actu
ally competing With the TES reaction. In these cases, the
riboZymes that have bound radiolabeled 5' exon regions, and
for Which the 3' exon region has dissociated, are binding and

reaction on MgCl2 concentration, time, and rP-8/4x concen
tration is shoWn in FIG. 3B. The kobs for the ?rst and second
step of the reaction are 1.69 and 0.05 min_l, respectively. The

riboZyme for maximal activity (With 1.33 nM substrate).
These results shoW that the rP-8/ 4x riboZyme, in the absence
of a nucleotide cofactor, inherently contains the ability to bind
a substrate in trans and catalyZe the TES reaction.
Even though there are 18 other uridines that could be sites
of 5' cleavage and four other guanosines that could be sites of

3' splicing for the 36-mer substrate, only the expected TES

is 2.5 times more likely to bind the riboZyme and be a sub
strate in the second reaction step than the 30-mer 3' exon

intermediate (data not shoWn). The results (FIG. 5) shoW that

a substrate in trans and catalyZe the excision-splicing reac
tion.

reaction is complete after 40 minutes and only requires 20 nM

Likewise, to test for 3' exon intermediate dissociation and
rebinding betWeen the tWo reaction steps, TES reactions Were
conducted With 166 nM rP-8/4x, 1.33 nM radiolabeled
36-mer, and a 50 (66.5 nM) or 500 (665 nM) fold excess ofa
non-radiolabeled 3' exon mimic competitor, r(GUGCUCU)

mediate dissociates from the riboZyme, the 7-mer competitor
50

mediated 3' splice site hydrolysis product at 26 nucleotides.
Nonetheless, the rP-8/4x riboZyme contains the ability to bind
Apparently, a majority of the 36-mer substrate undergoes
only the ?rst step of the reaction. The dependence of the TES

the riboZyme betWeen the tWo steps (for those 5' exon inter

(SEQ ID NO: 16), Which Would form a 10-mer competition
product. At equal molar concentrations if the 3' exon inter

trans-excision-splicing reaction (5' cleavage), and indicates
the reaction. Also produced is a small amount of riboZyme

then rebind the riboZyme before the exon ligation step. To test
for 5' exon dissociation and rebinding betWeen the tWo steps,
TES reactions Were conducted With 166 nM rP-8/4x, 1.33 nM
non-radiolabelled 36-mer, and 1.33 nM radiolabeled 5' exon,
r(AUGACU) (SEQ ID NO:15). In this case, if the 5' exon
intermediate dissociates from the riboZyme, the radiolabeled
5' exon is just as likely to then bind the riboZyme and form the

mediates that undergo the complete reaction).

assays). This band Was extracted from the gel matrix, repuri
?ed, and subjected to enZymatic sequencing, along With a
sequence and banding patterns Were identical (FIG. 4), indi
cating that the expected trans-excision-splicing product Was

C.). Interestingly, maximum TES product formation occurs
With as little as 20 nM riboZyme (at 44° C.), indicating that for
?nal product formation the 5' and 3' exon intermediates pro

16-mer product as the non-radiolabeled 5' exon intermediate.
As seen in FIG. 5, no radiolabeled TES products are observed,
indicating the 5' exon intermediate does not dissociate from

optimiZed MgCl2 concentration (7 mM) and the temperature
(440 C.) are shoWn in FIG. 3A.
The expected product band at 16 nucleotides in length Was
obtained in a yield of 25%:5% (for 6 independently run

mimic r(GUGCUCU) (SEQ ID NO:16) (Kdz20 uM at 37°

duced during the 5' cleavage step might not dissociate and

carinii, catalyZes the trans-excision-splicing reaction, a sub
strate Was designed that Would bind the rP-8/4x riboZyme’s

Previous studies utiliZing the rP-8/4x riboZyme (Testa, S.
M., GryaZnov, S. M. & Turner, D. H. (1998) Biochemistry 37,
9379-9385) shoW that the 5' exon mimic r(AUGACU) (SEQ

reacting With a small amount of the huge excess of 3' exon

competitor. Therefore, the vast majority of substrates that
undergo the complete TES reaction do not have 3' exon inter
65

mediate dissociation and rebinding occurring betWeen the
tWo steps of the reaction. Apparently, substrates that undergo
only the ?rst reaction step do so because of nearly irreversible
5' or 3' exon intermediate dissociation. It folloWs that since

US 7,776,835 B2
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intermediates to the complete TES reaction do not dissociate
from the riboZyme, the TES reaction is intramolecular With

re-engineered riboZyme to excise the RNA triplet repeat
region Whose expansion is the causative agent of the effects of
the genetic disease, Myotonic Dystrophy. A riboZyme Was
designed to target the uridine immediately upstream of the

regard to substrate.

Example 3

repeats. Because there are ?ve successive guanosines imme
diately folloWing the repeats (Which could lead to a mixture of

Excision of a single nucleotide using the R carinii.

TES products), the ?rst guanosine doWnstream from the ?ve
successive guanosines Was targeted. The substrate bridge

riboZyme. In order to determine if a loWer limit exists to the

length of the excised region, We tested the TES reaction using

contained 5 CUG repeats, as this is the smallest number of

the rP-8/ 4x riboZyme With tWo neW substrates. One substrate

repeats thought to form the hairpin structure similar to that

is a 12-mer, r1 AUGACUGUGCUC) (SEQ ID NO: 7), and
Was designed to contain the minimum length bridging
sequence that could utiliZe the 2 base pair RE2 interaction (to
form the P90 helix) and the 3' guanosine thought to be
required for self-splicing (FIG. 2Bi). The other substrate is a
10-mer, r1 AUGACUGE) (SEQ ID NO: 8), Which can not
utiliZe the RE2 interaction, and from Which only one nucle

seen With the expanded transcripts. Myotonic Dystrophy
patients actually have greater than 15 CUG repeats. Never

theless, the riboZyme targets the ?anking regions and Would
be the same regardless of the number of triplet repeats. This
riboZyme is referred to as the rP-8/4x-MD riboZyme and this
substrate the 38-mer DMPK mimic. The results at the opti

mum MgCl2 concentration (13 mM) and temperature (440 C.)

otide Would be excised (FIG. 2B ii). The results (FIG. 3A)
shoW that, under the optimal conditions of 10 mM MgCl2 and
440 C., both the 12-mer and 10-mer reactions lead to the

are shoWn in FIG. 6A. A 10 nucleotide product Was obtained,
20

formation of the expected 9-mer products, as con?rmed by

enzymatic sequencing (data not shoWn). The optimiZed reac
tions produce 72%:3.9% product for the 12-mer substrate
and 69.3%:4.4% product for the 10-mer substrate (for 6
independently run assays). Thus, the rP-8/4x riboZyme can

signi?cant amount, indicating a reasonably speci?c reaction.
The 10-mer product Was extracted from the gel and enZymati
25

excise as little as a single nucleotide. The same approximate

yield is obtained using the 12-mer and 10-mer substrates
Which suggests that the role of forming the P90 helix is not

large in this case. Therefore, the RE2 interaction, although
perhaps bene?cial, is not required for sequence speci?c TES

30

reactions. In addition, the 12-mer and 10-mer substrates lead
to more than tWice the product as compared With the 36-mer

accessibility of the 3' guanosine of the bridge for the G-bind

min_l, respectively (note that these values are Within experi
35

structure, is substantially more effective than the 36-mer rP-8/
4x system, Which excises a 20-mer unstructured bridge. Thus,
40

To determine Whether each riboZyme has speci?city for its
intended target, TES reactions Were run using the rP-8/4x
MD riboZyme With the 36-mer P carinii substrate at 13 mM
45

MgCl2, and the rP-8/4x riboZyme With the 38-mer DMPK
mimic at 7 mM MgCl2, each at 440 C. (FIG. 6A). In addition,
the reaction Was run using the rP-8/4x-MD riboZyme at 7 mM

50

MgCl2 and another reaction using the rP-8/ 4x riboZyme Was
run at 13 mM MgCl2 (data not shoWn). In these reactions, not
even 5' cleavage products are observed, indicating that the
riboZymes have some speci?city for their intended target

55

maximum activity differs for all the reactions, they all occur
at or beloW that required (15 mM) for maximum activity for
the R carinii group I intron self-splicing reaction in vitro.

substrates. Although the MgCl2 concentration required for

al (1992) Science 255, 1253-1255; Harley, H. G., Rundle, S.
A., MacMillan, 1. C., Myring, 1., Brook, 1. D., CroW, S.,
Reardon, W., Fenton, I., ShaW, D. 1., & Harper, P. S. (1993)

While it Was knoWn that the sequence of RE1 could be modi

?ed in reactions mimicking the ?rst step of the self-splicing
reaction (14, 20, 21), it Was previously not knoWn that all

Am. .1. Hum. Genet. 52, 1164-1174).
60

Example 4

tem Was developed (FIG. 2Biii) for analyZing the ability of a

targets With large bridge regions are not necessarily poor
reaction substrates.

ing site of the riboZyme. Indeed, previous reports suggest that

The sequence speci?city of the P carinii riboZyme can be
altered. For the TES reaction to be useful, the recognition
elements must be mutable in order to target predetermined
sequences. Therefore, a truncated DMPK mimic model sys

mental error and the rate of the second step is likely limited by
the rate of the ?rst step). Interestingly, the excision of this

28-mer bridge, Which could include a triplet repeat hairpin

the ability of the G-binding site to bind this endogenous
guano sine drives the second step of the reaction (Mahadevan,

M., Tsil?dis, C., Sabourin, L., Shutler, G., Amemiya, C.,
Jansen, G., Neville, C., Narang, M., Barcelo, 1., O’Hoy, K., et

cally sequenced, along With a chemically synthesiZed version
of the expected product. The sequence and banding patterns
obtained (FIG. 4) shoW that the expected TES product is
being generated. Apparently, the riboZyme can be modi?ed
(at RE1, RE2, and RE3) to target non-native substrates. The
dependence of this reaction on MgCl2 concentration, time,
and rP-8/4x-MD concentration is shoWn in FIG. 6B. The kobs
for the ?rst and second step of the reaction are 0.41 and 0.44

substrate, implicating the longer bridging region (Which
includes the four 5' bases of the intron) as being detrimental
for this reaction. As the amount of substrate that undergoes at
least the ?rst reaction step is similar for all of the different
substrates, 3' exon intermediate dissociation for the 36-mer
likely accounts for the difference in extent of ?nal product
formation. The dependence of the 10-mer substrate reaction
on MgCl2 concentration, time, and rP-8/4x concentration is
shoWn in FIG. 3C. The kobs for the ?rst and second step of the
reaction are 4.12 and 2.89 min-l, respectively. In contrast to
that for the 36-mer, the reaction With the 10-mer substrate is
more favorable at MgCl2 concentrations greater than 7 mM,
and the second reaction step occurs approximately 50-fold
faster. The origin of this effect is unknown, but could be due
to the reduced steric hindrance of the smaller bridge on the
required conformational rearrangement betWeen the tWo
reaction steps. This could re?ect an increased a?inity or

as expected, in a yield of 61 .1%:4.6% (for 6 independently
run assays). Besides unreacted 6-mer generated from the ?rst
step of the reaction, no other products are produced to any

three recognition elements are modi?able. That these recog

nition elements completely specify binding and reactivity

65

indicates that they are the primary determinants of speci?city
betWeen the riboZyme and its substrate. In addition, bridging
regions of different sequences and lengths (1, 3, 20, and 28
nucleotides) have been excised, indicating that perhaps a 3' G

in the bridging region might be the only sequence require
ment for the excised segment.
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SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

<2ll> LENGTH:

21

33

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222>

LOCATION:

(13) . . (l8)

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4X
<400> SEQUENCE: l

cacgccgctt tcgggaacct ctatagtgag tcg

<2ll> LENGTH:

33

33

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222>

LOCATION:

(15) . . (21)

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4X
<400> SEQUENCE: 2

cgactcacta tagaggttcc cgaaagcggc gtg

<2ll> LENGTH:

33

25

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222>

LOCATION:

(11) . . (l2)

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4X
<400> SEQUENCE: 3

ggtatagtct tgcctctttc gaaag

<2ll> LENGTH:

25

25

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222>

LOCATION:

(14) . . (l5)

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4X
<400> SEQUENCE: 4

ctttcgaaag aggcaagact atacc

<2ll> LENGTH:

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized

25
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—cont inued

<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222>

LOCATION:

(13) . . (l5)

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4X
<400> SEQUENCE: 5

cgactcacta taggtgttcc cgaaagcggc

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222>

LOCATION:

(16) . . (l8)

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4X
<400> SEQUENCE: 6

gccgctttcg ggaacaccta tagtgagtcg

<2ll> LENGTH:

3O

12

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 7
augacugugc uc

<2ll> LENGTH:

l2

10

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 8
augacugcuc

l0

<2lO> SEQ ID NO 9
<2ll> LENGTH: 332

<2l3> ORGANISM: Pneumocystis carinii
<400> SEQUENCE: 9

gagggucaug aaagcggcgu gaaaacguua gcuagugauc uggaauaaau ucagauugcg

6O

acacugucaa auugcgggga agcccuaaag auucaacuac uaagcaguuu guggaaacac

120

agcuguggcc gaguuaauag cccuggguau aguaacaaug uugaauauga aucuuuugcg

180

agaugaaaug ggugauccgc agccaagucc uaagggcauu uuugucuaug gaugcaguuc

240

aacgacuaga uggcaguggg uauuguaagg aauugcaguu uucuugcagu gcuuaaggua

300

uagucuaucc ucuuucgaaa gaaagaguau au

332

<2lO> SEQ ID NO 10
<2ll> LENGTH: 36

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized

US 7,776,835 B2
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22
—cont inued

SEQUENCE: lO
augacu cacc uuuuuuuuuu uuugugcucu uaaggu

36

SEQ ID NO 11
LENGTH: 11
TYPE: RNA

ORGANISM: Pneumocystis carinii
SEQUENCE: ll
gagggu caua

L1

ll

SEQ ID NO 12
LENGTH: 38
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: l2
gggaau gcug cugcugcugc uggggggauc acagacca

38

SEQ ID NO 13
LENGTH: 11
TYPE: RNA

ORGANISM: Pneumocystis carinii
SEQUENCE: l3
cccu g

ll

SEQ ID NO 14
LENGTH: 16
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: l4
augacu cucu uaaggu

SEQ ID NO 15
LENGTH: 6
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: l5
augacu

SEQ ID NO 16
LENGTH: '7
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: 16
gugcuc

SEQ ID NO 17
LENGTH: 10
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized

16

